News
US-based biotechnology company TRex Bio has begun dosing healthy volunteers in a clinical trial of TRB-061 for atopic dermatitis (AD). TRB-061 is a tumour necrosis factor receptor 2 (TNFR2) agonist ...
SOUTH SAN FRANCISCO--(BUSINESS WIRE)--TRex Bio, Inc. (“TRexBio”), a biotechnology company decoding human tissue immune biology to create revolutionary therapeutics, today announced the close of an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback